51
Participants
Start Date
November 28, 2017
Primary Completion Date
March 23, 2022
Study Completion Date
June 13, 2022
Pirfenidone (PFD)
Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
Placebo (Plac)
Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
Mycophenolate Mofetil (MMF)
Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
Hospital for Special Surgery, New York
University of Pittsburgh, Pittsburgh
Georgetown University, Washington D.C.
Johns Hopkins University, Baltimore
Medical University of South Carolina, Charleston
Indiana University Health, Indianapolis
University of Michigan, Ann Arbor
Northwestern University, Chicago
University of Texas Medical School at Houston, Houston
University of Colorado, Aurora
University of Utah, Salt Lake City
University of California Los Angeles, Los Angeles
University of Washington Medical Center, Seattle
Harvard Medical School, Brigham & Women's Hospital, Boston
Boston University, School of Medicine, Boston
Rutgers University, New Brunswick
Collaborators (1)
University of Michigan
OTHER
Genentech, Inc.
INDUSTRY
University of California, Los Angeles
OTHER
Michael Roth
OTHER